Skip to main content

Open Access Association of Interleukin-18 Gene Promoter Polymorphism on the Risk of Cervix Carcinogenesis in North Indian Population

Cervical cancer is one of the most common neoplastic diseases affecting women, with a combined worldwide incidence of almost half a million new cases. Considering the fact that IL-18 plays an important role in the interactions among T cells, NK cells, and macrophages and induces IFN-γ production, efforts should be made to understand the clinical impact of IL-18 cytokine in patients with solid malignancies, as not much study has been conducted in cervix carcinoma. In this study, we have observed in GC genotype statistically significant marginal increased risk of developing of cervical cancer (OR 1.8, 95% CI 1.17‐2.76, p = 0.006). Similarly, when the GC with CC genotypes were combined results were once more statistically significant with borderline risk of developing cervix cancer (OR 1.6,95% CI 1.09‐2.50, p = 0.01). Likewise, we found statistically significant increased risk between cases and controls in GC genotype and passive smokers with risk of cervical cancer (OR 4.3, 95%CI 2.13‐8.99, p = 0.00001). Our investigation suggests that IL-18 gene −137 in different genotypes, as also in passive smokers, may increase risk of cervix carcinogenesis in north Indian women.

Keywords: Cervical cancer; Interleukin-18; PCR-SSP; Polymorphism

Document Type: Research Article

Publication date: 01 April 2008

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content